These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12227060)

  • 1. [ERBB2/HER2: from molecular to clinical oncology].
    Khanson KP; Imianitov EN
    Vopr Onkol; 2002; 48(2):137-45. PubMed ID: 12227060
    [No Abstract]   [Full Text] [Related]  

  • 2. The distinctive nature of HER2-positive breast cancers.
    Burstein HJ
    N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
    [No Abstract]   [Full Text] [Related]  

  • 3. What is the ideal HER2 test for Herceptin therapy?
    Jpn J Clin Oncol; 2000 Apr; 30(4):208-9, 211. PubMed ID: 10830993
    [No Abstract]   [Full Text] [Related]  

  • 4. Polysomy 17 and HER-2 amplification: true, true, and unrelated.
    Rosenberg CL
    J Clin Oncol; 2008 Oct; 26(30):4856-8. PubMed ID: 18794542
    [No Abstract]   [Full Text] [Related]  

  • 5. HER2 and surgery: more questions to answer.
    Spigel DR
    Lancet; 2003 Aug; 362(9383):502-3. PubMed ID: 12932377
    [No Abstract]   [Full Text] [Related]  

  • 6. Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?
    Arteaga CL
    J Clin Oncol; 2006 Aug; 24(23):3722-5. PubMed ID: 16847283
    [No Abstract]   [Full Text] [Related]  

  • 7. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
    Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
    J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Breast cancer].
    Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
    Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 inhibition: from discovery to clinical practice.
    Chang JC
    Clin Cancer Res; 2007 Jan; 13(1):1-3. PubMed ID: 17200331
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
    Paik S; Kim C; Wolmark N
    N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
    [No Abstract]   [Full Text] [Related]  

  • 11. Information for patients. HER2: what you need to know.
    Oncology (Williston Park); 2009 Jul; 23(8 Suppl):48a-48b. PubMed ID: 19860043
    [No Abstract]   [Full Text] [Related]  

  • 12. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy.
    Ross JS
    Drug News Perspect; 2009 Mar; 22(2):93-106. PubMed ID: 19330168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HER-2 diagnostics].
    Bánkfalvi A
    Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Focus on ERBB2.
    Benusiglio PR
    Pharmacogenomics; 2008 Jul; 9(7):825-8. PubMed ID: 18597646
    [No Abstract]   [Full Text] [Related]  

  • 15. An overview of HER2.
    Lohrisch C; Piccart M
    Semin Oncol; 2001 Dec; 28(6 Suppl 18):3-11. PubMed ID: 11774200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2 inhibitors: clinical results.
    Crinò L; Franceschi E; Scopece L
    Suppl Tumori; 2002; 1(6):S3-4. PubMed ID: 12658892
    [No Abstract]   [Full Text] [Related]  

  • 17. HER2-positive breast cancer: current treatment strategies.
    Perez EA; Baweja M
    Cancer Invest; 2008 Jul; 26(6):545-52. PubMed ID: 18584344
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
    Bult P; Tjan-Heijnen VC; van Krieken H
    Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274
    [No Abstract]   [Full Text] [Related]  

  • 19. Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.
    Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN
    Nat Clin Pract Oncol; 2005 Dec; 2(12):598-9. PubMed ID: 16341096
    [No Abstract]   [Full Text] [Related]  

  • 20. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.